SHANGHAI, China, March 29, 2023 – WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it had received 2023 CDMO Leadership Awards in the “Capabilities” category across all three groups – Overall, Big Pharma and Small Pharma. The company also was recognized for having exceeded customer expectations in the Individual Attribute Awards categories of “Accessible Senior Management” and “State-of-the-Art.”
WuXi Biologics won CDMO Leadership Award for the sixth consecutive year. The company has been relentlessly enhancing its integrated enabling platform with leading-edge technologies to expedite biologics discovery, development and manufacturing. In 2022, WuXi Biologics supported its global clients to obtain 123 Investigational New Drug (INDs) approvals, including a novel RNA product. Besides, the company increased its global capacity in 2022 to 262,000L, with new facilities in the U.S., Ireland and China coming online. Total capacity – across five countries – is expected to reach 580,000L by 2026 to meet strong customer demand. Geographic diversity will allow WuXi Biologics to provide more dynamic capabilities to serve its customers anywhere in the world.
Dr. Weichang Zhou, President of Global Biologics Development and Operations & CTO of WuXi Biologics received the award on behalf of the company
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We’re very pleased to be recognized by the CDMO Leadership Awards for the sixth consecutive year. It speaks to both the trust our global clients have in us and the dedication of our employees. We are committed to enabling our partners in delivering life-saving treatments quickly and effectively to the market, with the aim of benefiting patients worldwide.”
For the past 12 years, Outsourced Pharma and Life Science Leader have presented the annual CDMO Leadership Awards (previously called the CMO Leadership Awards) based on experiential feedback from sponsor companies. In a survey conducted by Industry Standard Research (ISR) Reports, biopharma customers provide ratings only for CDMOs with whom they have recently worked. For the 2023 CDMO Leadership Awards, 72 global contract manufacturers were evaluated on 23 performance metrics, covering all sizes of companies from both the Pharma and Biopharma industries.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of December 31, 2022, WuXi Biologics is supporting 588 integrated client projects, including 17 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com